Show simple item record

dc.contributor.authorElumalai, Thiraviyamen
dc.contributor.authorMaitre, Priyamvadaen
dc.contributor.authorPortner, Rbinen
dc.contributor.authorBilly Graham Mariam, Neethuen
dc.contributor.authorYoung, T.en
dc.contributor.authorHughes, S.en
dc.contributor.authorWickramasinghe, K.en
dc.contributor.authorBhana, R.en
dc.contributor.authorSabar, M.en
dc.contributor.authorThippu Jayaprakash, K.en
dc.contributor.authorMistry, Hiteshen
dc.contributor.authorHoskin, Peter Jen
dc.contributor.authorChoudhury, Ananyaen
dc.date.accessioned2023-07-05T09:10:57Z
dc.date.available2023-07-05T09:10:57Z
dc.date.issued2023en
dc.identifier.citationElumalai T, Maitre P, Portner R, Billy Graham Mariam N, Young T, Hughes S, et al. Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023 Jun 16;186:109746. PubMed PMID: 37330057. Epub 2023/06/18. eng.en
dc.identifier.pmid37330057en
dc.identifier.doi10.1016/j.radonc.2023.109746en
dc.identifier.urihttp://hdl.handle.net/10541/626374
dc.description.abstractPurpose: To evaluate clinical outcomes for cN1M0 prostate cancer treated with varied modalities. Materials and methods: Men with radiological stage cN1M0 prostate cancer on conventional imaging, treated from 2011-2019 with various modalities across four centres in the UK were included. Demographics, tumour grade and stage, and treatment details were collected. Biochemical and radiological progression-free survival (bPFS, rPFS) and overall survival (OS) were estimated using Kaplan Meier analyses. Potential factors impacting survival were tested with univariable log-rank test and multivariable Cox-proportional hazards model. Results: Total 337 men with cN1M0 prostate cancer were included, 47% having Gleason grade group 5 disease. Treatment modalities included androgen deprivation therapy (ADT) in 98.9% men, either alone (19%) or in combinations including prostate radiotherapy (70%), pelvic nodal radiotherapy (38%), docetaxel (22%), or surgery (7%). At median follow up of 50 months, 5-year bPFS, rPFS, and OS were 62.7%, 71.0%, and 75.8% respectively. Prostate radiotherapy was associated with significantly higher bPFS (74.1% vs 34.2%), rPFS (80.7% vs 44.3%) and OS (86.7% vs 56.2%) at five years (log rank p < 0.001 each). On multivariable analysis including age, Gleason grade group, tumour stage, ADT duration, docetaxel, and nodal radiotherapy, benefit of prostate radiotherapy persisted for bPFS [HR 0.33 (95% CI 0.18-0.62)], rPFS [HR 0.25 (0.12-0.51)], and OS [HR 0.27 (0.13-0.58)] (p < 0.001 each). Impact of nodal radiotherapy or docetaxel was not established due to small subgroups. Conclusion: Addition of prostate radiotherapy to ADT in cN1M0 prostate cancer yielded improved disease control and overall survival independent of other tumour and treatment factors.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.radonc.2023.109746en
dc.titleImpact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysisen
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.en
dc.identifier.journalRadiotherapy and Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record